צמיחת הכנסות ב-12 חודשים נגררים: Citius Pharmaceuticals (CTXR)

The YoY sales volume growth trajectory over the rolling period confirms Citius Pharmaceuticals (CTXR) business dependence on the final stages of drug trials. The 0.00 mark serves as a current indicator influenced by FDA delays and capital shortages. Meanwhile, patent protection for infection treatment methods cushions the decline, creating barriers for competitors in the hospital sector.
Citius Pharmaceuticals, Inc. - פילוחים אנליטיים ומדדי מפתח (CTXR)

Value investing involves searching for early signals of a fundamental business turnaround. This indicator measures revenue dynamics over a rolling year, allowing for the real-time tracking of income recovery rates. For Citius Pharmaceuticals (CTXR), such a metric is critical during the market launch of Mino-Lok and hospital sector drugs. Growth confirms the commercial success of new products. Analyze the last twelve months (LTM) change in commercial revenue to assess the sustainability of the expansion.